Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab

This article has no abstract
Epistemonikos ID: 75b3e1d57c9081d731f5815c3c6cc37f00299bfb
First added on: Feb 19, 2025